





### Indian Bank BUY

Sector: Banks/Mid Cap | Earnings Update – 1QFY22 22 July 2021

**Background**: Indian Bank features among the mid-sized banks in the public sector space. As of 1QFY22, the bank had business of about ₹9.2tn operating through a network of 5,809 branches. Prior to amalgamation with Allahabad bank, Indian Bank's footprint was largely skewed towards the southern states of Tamil Nadu, Karnataka, Andhra Pradesh and Kerala. Now the combined entity has a stronger presence in Central and Eastern states of India too. With RoA of ~0.75%, the bank features amongst the most profitable banks in the PSU space. The bank has positioned itself as a bank with focus on retail and mid corporate segment.

| Sensex                   | 52,198            |
|--------------------------|-------------------|
| Nifty                    | 15,632            |
| Price                    | ₹ 140             |
| Target Price (12 months) | ₹ 170             |
| Recommendation           | BUY               |
|                          |                   |
| 52 Week High/Low         | ₹ 156.9/53.2      |
| Bloomberg / Reuters      | INBK IN / INBA.BO |
| Equity (shares in mn)    | 1,245.4           |
| Mkt. Cap in bn           | ₹ 157.2/ \$ 2.1   |
| Avg. Daily Vol. ('000)   | 4,995.2           |
| Avg. Daily Vol. (mn)     | ₹ 699.3 /\$ 9.3   |
|                          |                   |

| Shareholding                   | Jun-20 | Mar-21 | Jun-21 |
|--------------------------------|--------|--------|--------|
| Promoters (%)                  | 88.1   | 88.1   | 79.9   |
| FII (%)                        | 1.0    | 1.0    | 2.9    |
| DII (%)                        | 4.0    | 4.4    | 10.5   |
| Others (%)                     | 6.9    | 6.6    | 6.7    |
| Pledge (% of promoter holding) | 0.0    | 0.0    | 0.0    |

| Valuation Summary (₹ bn) |       |       |       |  |  |
|--------------------------|-------|-------|-------|--|--|
| Y/E March                | 2021  | 2022E | 2023E |  |  |
| Net Interest Inc         | 156.7 | 170.2 | 194.7 |  |  |
| Other Inc                | 65.4  | 66.9  | 82.6  |  |  |
| Pre Prov Profit          | 114.2 | 138.4 | 158.0 |  |  |
| PAT                      | 30.2  | 44.1  | 60.6  |  |  |
| EPS (₹)                  | 26.7  | 35.4  | 48.7  |  |  |
| EPS growth (%)           | 86.3  | 32.5  | 37.5  |  |  |
| PE (X)                   | 5.2   | 4.0   | 2.9   |  |  |
| P /ABV (X)               | 0.6   | 0.6   | 0.6   |  |  |
| Div Yield (%)            | -     | 1.1   | 1.1   |  |  |
| ROA (%)                  | 0.5   | 0.7   | 0.8   |  |  |
| ROE (%)                  | 8.2   | 10.6  | 12.7  |  |  |
| CAR (%)                  | 15.7  | 14.1  | 14.1  |  |  |
|                          |       |       |       |  |  |
| Performance(%)           | 1M    | 3M    | 12M   |  |  |
| INDIAN BANK              | -5.3  | 33.9  | 123.2 |  |  |

| SENSEX   |  | -0.7                       | 7.0       | 37.6   |
|--|--|----------------------------|-----------|--|
| Aug-20<br>Sep-20<br>OG-20<br>OG-20<br>OG-20<br>Aug-20<br>OG-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Aug-20<br>Au | Nov-20 - Pec-20 - Pec-21 - Pec | Mar-21 - Apr-21 - May-21 - | Jul-21 -  | 56,000<br>53,000<br>50,000<br>47,000<br>44,000<br>41,000<br>38,000<br>35,000 |
|  | INDIAN DAINK   |                            | - JLINJL/ | `  |

# Steady quarter: Improvement in NIM and lower opex boosted operating performance while tax reversal propped up PAT; For FY22 bank is targeting 10%-12% credit growth and slippage ratio below 3%

- In 4QFY21 Indian bank's total advances growth remain muted (6%/0%% YoY/QoQ) to ₹3.7tn. The domestic loan book increased 6% YoY, buoyed by growth in Agri segment, up 17% YoY and MSME up 12% YoY. The Corporate advances (42% of loan book) registered a decline of 3% YoY primarily on account of bank's cautious lending approach and weak demand in the private sector. The management remains optimistic of recovery in corporate lending beginning 2QFY22. For FY22 the bank expects credit growth to be in the range of 10-12%, mainly driven by RAM segment.
- Deposits during the quarter stood at ₹5.4tn (+10% YoY) led by growth in term deposits (12% YoY). However CASA deposits growth (flat QoQ) was marginally weaker than previous quarter due to seasonality and stood at ₹2.2tn (+9% YoY). This led to a small dip in CASA ratio to 41% (down 64 bps QoQ). The bank continues to enjoy a high CASA ratio compared to peers owing to its merger with Allahabad Bank leading to lower Cost of Funds. The management is optimistic of CASA ratio improvement in the coming quarters. During the quarter, the Net interest income (NII) registered strong growth of 20% sequentially (3% YoY) and stood at ₹39bn. This led to increase in NIM to 2.85% (+ 51bps QoQ). The management intends to take the NIM to 3%. Yield on advances improved by 79bps QoQ to 7.06%. In addition, the cost of funds remained stable at 4.08% (flat QoQ) owing to growth in CASA deposits and increasing term deposits at lower rates.
- The bank's asset quality remained stable despite increase in slippages. The slippages stood at 5% (annualized) vs 9% in 4QFY21 with majority of stress arising from MSME. Slippages are expected to remain marginally higher in FY22. The management aims to keep slippage below 3% going forward. The bank expects additional restructuring worth ₹4-5bn in the MSME book. Segment wise restructuring: Retail- ₹3.2bn, MSME- ₹13.4bn.
- Headline GNPA ratio improved to 9.69% in 1QFY22 (vs 9.85% in 4QFY21) led by higher upgrades (₹16bn) and write-offs (₹28bn). However NNPA increased by 10bps QoQ to 3.47% in 1QFY22. The bank's collection efficiency (CE) declined in May-June 2021 however recovered in July 2021. Segment wise CE stood at: Retail-85%, MSME-78%, Agri-88% and Corporate 97%. The management expects CE to exceed 90% in 2QFY22.
- In 4QFY21, Non-interest income increased to ₹18bn (up 8% QoQ), partly due to profit on sale of investment (up 35% QoQ) and recovery of bad debts (up 12% QoQ). In addition the amalgamation with Allahabad Bank has accrued cost synergies leading to improvements in Cost to Income ratio to 40.86% (vs 47.06% 1QFY21).
- During the quarter, the bank reported operating profit of ₹34.9bn (up 26% YoY) on account of robust increase in Non-Interest Income (+8% QoQ) and lower opex (down 5.6% QoQ). The bank's provisions continue to remain elevated at ₹26bn (vs ₹21bn in 1QFY21). However tax reversal of ₹3bn supported PAT, which stood at ₹11.9bn. PCR stood at 82% (vs 80.5% in 1QFY21).

Valuation: The bank's improving collection efficiencies and less than expected restructuring have improved credit cost outlook. In addition, the anticipated recovery in corporate demand should support the credit off take in 2HFY22E. The bank with its strong capital base remains well placed to benefit from expected economic revival in the coming quarters. The bank's performance has been good despite the current economic scenario and presents a stable outlook for the bank. We expect earnings to grow on the back of improved margins and offtake in credit demand. Assigning a P/ABV of 0.6x for FY23E, we maintain our target price of ₹170 and BUY rating on the stock.

Risks: Fresh slippages arising from stressed sectors, recoveries being delayed and lower than anticipated growth in advances.

Results Summary 1QFY22

| Y/E March (₹ bn)        | 1QFY22 | 1QFY21 | YoY Growth | 4QFY21 | QoQ Growth |
|-------------------------|--------|--------|------------|--------|------------|
| Net Interest Income     | 39.9   | 38.7   | 3.1%       | 33.3   | 20.0%      |
| Other Income            | 19.8   | 13.3   | 49.6%      | 18.3   | 8.7%       |
| Pre Provisioning Profit | 34.9   | 27.5   | 26.8%      | 25.2   | 38.6%      |
| PAT                     | 12.0   | 3.69   | 224.1%     | 16.8   | -28.8%     |
| Cost/Income (%)         | 40.9   | 47.1   |            | 49.8   |            |
| Gross NPA (%)           | 9.7    | 10.9   |            | 9.9    |            |
| Net NPA (%)             | 3.5    | 3.8    |            | 3.4    |            |
| Prov Coverage ratio (%) | 82.0   | 80.5   |            | 82.1   |            |
| CAR (%)                 | 15.9   | 13.5   |            | 15.7   |            |

Arjun Prasad Pasumarthi

+91-44-40047363

arjunpp@chola.murugappa.com



## DISCLOSURES/ APPENDIX I. ANALYST CERTIFICATION

I, Arjun Prasad Pasumarthi hereby certify (1) that the views expressed in this research report accurately reflect my personal views about any or all of the subject securities or issuers referred to in this research report, (2) No part of my compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report by Cholamandalam Securities Limited or its Group/associates companies. (3) has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations.

| Disclosure of Interest Statement           | Update |
|--|--------|
| Analyst holding in the stock               | No     |
| Served as an officer, director or employee | No     |

#### II. ISSUER SPECIFIC REGULATORY DISCLOSURES, Unless specifically mentioned in Point No. 9 below:

- 1. The Research Analyst(s), Cholamandalam Securities Limited (CSL), Associate of Analyst or his relative does not have any financial interest in the company(ies) covered in this report.
- 2. The Research Analyst, CSL or its associates or relatives of the Research Analyst associates collectively do not hold more than 1% of the securities of the company (ies) covered in this report as of the end of the month immediately preceding the distribution of the research report.
- 3. The Research Analyst, his associate, his relative and CSL do not have any other material conflict of interest at the time of publication of this research report.
- 4. The Research Analyst, CSL and its associates have not received compensation for investment banking or merchant banking or brokerage services or for any other products or services from the company(ies) covered in this report, in the past twelve months.
- 5. The Research Analyst, CSL or its associates have not managed or co-managed in the previous twelve months, a private or public offering of securities for the company (ies) covered in this report. \
- 6. CSL or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party, in connection with the research report.
- 7. The Research Analyst has not served as an Officer, Director or employee of the company (ies) covered in the Research report.
- 8. The Research Analyst and CSL has not been engaged in market making activity for the company(ies) covered in the Research report.
- 9. Details CSL, Research Analyst and its associates pertaining to the companies covered in the Research report:

| Sr.No. | Particulars  | Yes/No |
|--------|--|--------|
| 1      | Whether compensation has been received from the company(ies) covered in the Research report in the past 12 months for investment banking transaction by CSL  | No     |
| 2      | Whether Research Analyst, CSL or its associates or relatives of the Research Analyst associates collectively hold more than 1% of the company(ies) covered in the Research report  | No     |
| 3      | Whether compensation has been received by CSL or its associates from the company(ies) covered in the Research report   | No     |
| 4      | CSL or its associates have managed or co-managed in the previous twelve months a private or public offering of securities for the company(ies) covered in the Research report  | No     |
| 5      | Research Analyst, his associate, CSL or its associates have received compensation for investment banking or merchant banking or brokerage services or for any other products or services from the company(ies) covered in the Research report, in the last twelve month  | No     |
| -      | the second of the desire of the second of th |        |

10. There are no material disciplinary action that been taken by any regulatory authority impacting equity research analysis activities.

#### STOCK RATINGS

BUY: The stock's total return is expected to exceed 15% over the next 12 months.

OUT PERFORMER: The stock's total return is expected to be within 5-15% over the next 12 months.

MARKET PERFORMER: The stock's total return is expected to be between -5% to +5% over the next 12 months.

UNDER PERFORMER: The stock's total return is expected to be between -15% to -5% over the next 12 months.

SELL: The stock's total return is expected to more than -15% over the next 12 months.

#### III. DISCLAIMER

The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy completeness or correctness.

This document is for information purposes only. This report is based on information that we consider reliable, but we do not represent that it is accurate or complete, and one should exercise due caution while acting on it. Descriptions of any company or companies or their securities mentioned herein are not complete and this document is not, and should not be construed as an offer or solicitation of an offer to buy or sell any securities or other financial instruments.

Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. All opinions, projections and estimates constitute the judgment of the author as on the date of the report and these, plus any other information contained in the report, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. This report is intended for distribution to institutional investors.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject to CSL or its associates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently send or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. Neither this document nor any copy of it may be taken or transmitted into the United State (to U.S.Persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof.

Any unauthorized use, duplication, redistribution or disclosure of this report including, but not limited to, redistribution by electronic mail, posting of the report on a website or page, and/or providing to a third party a link, is prohibited by law and will result in prosecution. The information contained in the Report is intended solely for the recipient and may not be further distributed by the recipient to any third party.

CSL generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, CSL generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member

of any companies that the analysts cover. Our salespeople, traders, and other professionals or associates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein. Our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

The views expressed in this research report reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The compensation of the analyst who prepared this document is determined exclusively by CSL however, compensation may relate to the revenue of CSL, of which sales and trading are a part. Research analysts and sales persons of CSL may provide important inputs to its affiliated company(ies).

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. CSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report including but not restricted to fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc

CSL and its associates, officers, directors, and employees subject to the information given in the disclosures may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation (financial interest) or act as a market maker in the financial instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential material conflict of interest with respect to any recommendation and related information and opinions. The views expressed are those of the analyst and the Company may or may not subscribe to the views expressed therein.

CSL, its associates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall CSL, any of its associates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. The Company accepts no liability whatsoever for the actions of third parties.

The Report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Report refers to website material of the Company, the Company has not reviewed the linked site. Accessing such website or following such link through the report or the website of the Company shall be at your own risk and the Company shall have no liability arising out of, or in connection with, any such referenced website

CSL shall not be liable for any delay or any other interruption which may occur in presenting the data due to any technical glitch to present the data. In no event shall the CSL be liable for any damages, including without limitation, direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by CSL through this presentation.

Neither CSL, nor any of its other group companies or associates, shall be responsible for any decisions taken on the basis of this report. Investors are advised to consult their Investment and Tax consultants before taking any investment decisions based on this report.

| RESEARCH                |                        |                    |                                |  |
|-------------------------|------------------------|--------------------|--------------------------------|--|
| Kedar S Kadam           | DGM & Head of Research | +91-44 - 4004 7361 | kedarsk@chola.murugappa.com    |  |
| Mugilan K               | Technical Analyst      | +91-44 - 4004 7353 | mugilank@chola.murugappa.com   |  |
| Arjun Prasad Pasumarthi | Fundamental Analyst    | +91-44 - 4004 7363 | arjunpp@chola.murugappa.com    |  |
| Nilesh Patil            | Fundamental Analyst    | +91-44- 4004 7266  | nileshmp@chola.murugappa.com   |  |
| Ammar Haider            | Associate              | +91-44 - 4004 7360 | amarh@chola.murugappa.com      |  |
| Arvind Sai M            | Associate              | +91-44 - 4004 7360 | arvindsm@chola.murugappa.com   |  |
|                         |                        |                    |                                |  |
| Balaji H                | Compliance Officer     | 044-30007226       | balajih@chola.murugappa.com    |  |
| Gayathri Devi           | Customer service       | 1800 425 4477      | gayathrids@chola.murugappa.com |  |

